Narukawa, T.; Yasuda, S.; Horinaka, M.; Taniguchi, K.; Tsujikawa, T.; Morita, M.; Ukimura, O.; Sakai, T.
The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma. Cancers 2024, 16, 4058.
https://doi.org/10.3390/cancers16234058
AMA Style
Narukawa T, Yasuda S, Horinaka M, Taniguchi K, Tsujikawa T, Morita M, Ukimura O, Sakai T.
The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma. Cancers. 2024; 16(23):4058.
https://doi.org/10.3390/cancers16234058
Chicago/Turabian Style
Narukawa, Tsukasa, Shusuke Yasuda, Mano Horinaka, Keiko Taniguchi, Takahiro Tsujikawa, Mie Morita, Osamu Ukimura, and Toshiyuki Sakai.
2024. "The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma" Cancers 16, no. 23: 4058.
https://doi.org/10.3390/cancers16234058
APA Style
Narukawa, T., Yasuda, S., Horinaka, M., Taniguchi, K., Tsujikawa, T., Morita, M., Ukimura, O., & Sakai, T.
(2024). The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma. Cancers, 16(23), 4058.
https://doi.org/10.3390/cancers16234058
